Detectable levels of the inhibitor were found in the brains of PD mice, suggesting that the therapeutic effects seen in the PD mice after systemic injection of the SGK1 inhibitor occurred because the inhibitor permeated into the brain and acted on the glia there. Here, SGK1 is linked to Parkinson disease.